SciBase Holding AB Announces Significant Capital Raise
SciBase Holding AB, known for its innovative dermatology solutions, has recently embarked on a capital raise endeavor. This strategic move aims to generate approximately SEK 81.8 million. The funds are to be raised through a combination of directed share issues and rights issues, showcasing the Company's commitment to expanding its offerings in the healthcare sector.
Details of the Capital Raise
The capital raise will encompass two main components: a directed share issue amounting to about SEK 22.5 million and a rights issue approximately valued at SEK 59.3 million. The directed issue will allow the Company to generate resources while slightly deviating from the existing shareholders’ preferential rights. Meanwhile, the rights issue empowers current shareholders to maintain their stakes in the Company.
Newly Approved Prospectus
As part of this venture, an EU Growth Prospectus has been crafted and received approval from the Swedish Financial Supervisory Authority. This document presents crucial information regarding the capital raise, detailing the terms and conditions of the rights issue, and will be made accessible to the public through SciBase's website.
Timetable for Participation
The Company has outlined a clear timetable for stakeholders interested in participating in the rights issue. The record date for participation will be firmly established, followed by a defined period for trading in unit rights and subscription. This structured approach demonstrates SciBase's transparency and commitment to engaging its investors effectively.
Role of Advisors
In conjunction with this capital raising process, SciBase has engaged reputable advisors to guide its financial strategies. Penser by Carnegie is serving as the financial advisor, while Advokatfirman Schjødt has been retained for legal expertise. This collaboration underscores the Company’s dedication to adhering to best practices in capital management.
Commitment to Dermatology Innovations
SciBase is renowned for its dedication to advancing dermatology through rigorous research and state-of-the-art technology. The Company specializes in early detection and prevention, primarily through its flagship product, Nevisense. This cutting-edge platform leverages artificial intelligence combined with advanced electrical impedance spectroscopy technology, significantly enhancing diagnostic precision.
Future Outlook
The recent capital raise initiative not only supports SciBase’s immediate financial goals but also sets the stage for further innovations in skin health management. By increasing funds, SciBase aims to broaden its research and development efforts, ultimately expanding its service offerings and market reach.
About SciBase
SciBase Holding AB is at the forefront of medical technology, committed to improving patient care through innovative solutions in dermatology. With a foundation built on more than two decades of research at the esteemed Karolinska Institute, the Company's mission revolves around minimizing patient suffering while empowering clinicians to provide timely and effective care. This approach not only leads to improved patient outcomes but also contributes to reducing overall healthcare costs.
Frequently Asked Questions
What is the purpose of the capital raise by SciBase?
The capital raise aims to generate funds that will support the company’s growth initiatives and ongoing innovations in dermatological technology.
Where can I find the approved prospectus?
The approved prospectus will be accessible on the SciBase website, detailing the terms and conditions of the associated rights issue.
Who are the financial advisors for SciBase?
SciBase has appointed Penser by Carnegie as their financial advisor and Advokatfirman Schjødt for legal advisory services related to the capital raise.
What is Nevisense?
Nevisense is SciBase's flagship product, a point-of-care platform that combines AI with advanced EIS technology to enhance diagnostic accuracy in dermatology.
How has SciBase impacted the healthcare market?
SciBase's innovations have significantly improved the early detection and management of skin conditions, contributing to better patient outcomes and reduced healthcare costs.
